Thank you, operator, and good afternoon to all of you. Our performance in the third quarter clearly reflects the impact of our ongoing efficiency initiatives, including the improved capital structure finalized during the first half of this year. Cash flow and earnings were in line with our expectations. The top line growth was somewhat soft in the quarter, mainly due to a single large order of lab equipment for Eli Lilly worth 23 million, which was invoiced in Q3 2024. Despite that, we saw strong momentum in our healthcare, consumables, and clinical trials business. We continue to see healthy demand for medical equipment across Europe as well as in North and South America.
From a global perspective, 2025 has been turbulent so far, with friction in world trade and ongoing geopolitical tensions. We are closely monitoring these developments but choose to focus on things we can influence, and that is why we continue to work hard every day to create value for our customers and shareholders as efficiently as possible. We are also experiencing headwinds from the strengthening of the Swedish krona, which has impacted both our top line and earnings through translation effects. Looking ahead, our focus remains clear, strong, and growing. Cash flow generated by our existing group companies enables us to acquire additional cash flow and drive long-term shareholder value. With that, let's take a closer look at our Q3 results. Our net sales came in at 363 million SEK, which took us to a year-over-year decline of 4.8%. Adjusted for FX and excluding certain factors, our order intake in the quarter declined by 17%, or 12% when FX adjusted, mainly due to the large order from Saab in Q3 2024, which was 32.5 million. The year-to-date figure is also impacted by the larger Clean Rooms orders we received last year. Within the lab segment. Order intake for the quarter showed healthy growth of roughly 14%, but the year-to-date figures were heavily affected by last year's record Clean Rooms orders. Orders are the largest ever within the business area. We will continue to see some volatility in order intake, given the project nature of these larger orders. However, excluding the impact of Eli Lilly and the clean room orders.
Our year-to-date order intake showed slight growth. It is also important to note that order intake is not a relevant leading indicator for most of our businesses, since we deliver continuously against orders rather than building backlog. EBITA came in at 56 million SEK, in line with last year. This takes us to a margin of 16%, stronger than Q3 last year, where we reached roughly 14%. Looking at the cash flow from operations, it came in strong at 35 million SEK. A big contributor was lower financing expenses. 21 million versus 44 for Q3 last year.
Net leverage for the end of the period was 3.2 times, an increase from three times last quarter, mainly affected by paid earnouts. Adjusted net profit came in at 19 million, compared to minus five in Q3 last year. Again, lower financial costs, lower tax, and increased operational efficiency were the drivers. These were the drivers. Coming into the commercial and operational highlights of this quarter, we saw balanced business momentum in both healthcare and lab. During the quarter, we continued to focus on efficiency initiatives to ensure that we are maximizing our potential to drive value. EBITDA and EBITDA margin improved year over year, as the margin came in at 15.5% compared to 13.7%, driven mainly by product mix and efficiency improvements. Managing working capital is one of our top priorities. During the quarter, we saw a healthy increase in cash flow compared to the same quarter last year.
As mentioned before, lower financial expenses, lower tax payments, and moderate working capital build, which came in at 5.5 million SEK. The main drivers in terms of geography were approximately half, or 47%, of our sales in the quarter coming from the US or North America. And our second largest market is Europe, and the third is South America.
Looking at our sales by product category, the top three for the quarter are Laboratory Equipment at 36%, Medical Consumables at 37%, and Medical Equipment at 22%. High activity in medical equipment and continued balanced demand in clinical trials.
Lab equipment is, as mentioned earlier, affected by tough comparables due to the sale of 2.5 to 2.1 million EUR to Eli Lilly in Q3 last year. Splitting the group into healthcare and lab, and looking at healthcare, our sales came in at 234 million SEK in the quarter. Organic growth was close to flat. It was 0.2% FX adjusted and -6.2% non-adjusted. Looking at the year-to-date figure, we saw an organic decrease of -1.4%.
Adjusted for FX, there is a growth of 4.2%. The lab segment reported sales of 129 million SEK for the quarter. Organic sales came in at -16.2%, FX adjusted.
We ended up at -12.7%. Looking at profit margins, healthcare came in at a 16% EBITDA margin and lab at 17.2% in the quarter. Isolated. Looking at net sales by geography for the healthcare segment.
North America continues to be a key market with approximately 60% of sales, and it is expected to remain so for a long time. Europe has shown good development in the lab segment. Europe is the largest market followed by the US.
We remain focused on profitable growth, stable returns and maintaining well-balanced debt levels.
We remain focused on profitable growth, stable returns, and maintaining well-balanced debt levels. A strong emphasis is placed on EBITDA growth and return on capital employed as our key financial performance indicators. Long-term EBITDA growth will be driven by a combination of organic expansion and strategic acquisitions.
Our long-term target is to double EBITA every five years.
We are committed to maintaining a maximum net debt to EBITDA ratio of three times. While a dividend remains part of our long-term financial framework. Distributions will be considered only once all other long-term financial targets are met at a sustainable and appropriate level. I'm now handing over to Johan to take you through the group's financial performance.
We are committed to maintaining a maximum net debt to EBITDA ratio of three times. Thank you, Staffan, and good afternoon, everyone. I'm happy to be here today and take you through the figures for the third quarter of 2025. EBITDA, which is ADDvise Group's main metric for measuring profit, gives a fair view of the financial performance of our companies. EBITDA is defined as operating profit before amortization, impairment expenses, and revaluations related to acquisitions, as well as non-recurring items. And just as a reminder, EBITDA is our key metric from this year, 2025, and figures in this graph have been historically adjusted with the new definition. And EBITDA in the third quarter amounted to 56 million, which corresponds to a margin of 15.5%. EBITDA has improved by 1 million compared to the same period last year, and the EBITDA margin has improved to 15.5% compared to 13.7% last year. And I'm happy to see that profit is increasing despite currency headwinds from both US dollars and Brazilian reais. This is thanks to all of our companies working hard every day to improve operational efficiency with a focus on profit, profitability, and cash flow, which is the key to our long-term performance. As we have pointed out in earlier reports, 2024 faced tough comparables from 2023.
The individual quarters of 2024 should be considered at a normal level of profits, which means that from Q4 2024 onwards, we see normalized levels of sales and profitability.
Profitability on a rolling 12-month basis, and for the last 12 months, EBITDA amounts to 268 million, which corresponds to a margin of 16.5%. Moving on to cash flow and capital efficiency.
And here, when we talk about cash generation, we look at the underlying cash flow generated by our businesses, with deductions from changes in working capital as well as depreciation and investments in our asset base, including lease payments.
In the third quarter, we see a moderate working capital build of 5.5 million, mainly driven by an increase in accounts receivable. Working capital efficiency and optimization is and will always be a key focus area for us and our companies. Depreciation includes depreciation on fixed assets as well as on right-of-use assets related to leases, and the net between depreciation, leases, and investments is 2.3 million, indicating lower new investments compared to depreciation on existing assets, mainly driven by lower investments this year in production efficiency in South America, as well as the clinical trial business compared to last year.
Total cash generation from operations in the quarter was 53 million, relative to an EBITDA of 56 million.
We consider this a solid and satisfactory level of cash generation in the quarter, and a testament to our never-ending focus on cash flow return on capital employed, which measures profitability and how efficiently we use our capital. Our capital was 12% in the quarter, and this is one of our long-term financial targets with a long-term goal of 15% return on capital employed. Moving on to the financial position here, our long-term target is three times net debt over EBITDA. And net leverage at the end of Q3 was 3.2 times EBITDA. The new capital structure means significantly lower financing costs, which improves operating cash flow and reduces net leverage over time. Total financing expenses in Q3 were 21 million SEK compared to 44 million last year. In this quarter, this effect was offset by Earnout transactions, and the rights issue for the first half of this year added 457 million before transaction costs to the company. It also included warrants that could potentially add up to 114 million SEK to the company, or up to a maximum of 172 million in Q1 2026 if all warrants are fully exercised. Available liquidity is good.
Cash at the end of the quarter was 131 million SEK.
SEK, with an additional 114 million available in unused credit facilities.
And that's all from me. I will now hand over to Staffan for some closing remarks.
Thank you, Johan. I will summarize and give you our takeaways from this quarter before we open up for questions.
We delivered solid cash generation in the third quarter. Organic sales declined by 4.8%. FX adjusted mainly due to the larger Eli Lilly order in Q3 2024, but EBITA still improved despite FX headwinds supported by operational efficiency and a stronger product mix. This was also the first quarter with the full effect of our improved capital structure, resulting in roughly 50% lower financial expenses.
On the M&A side, we continue to evaluate interesting opportunities, including bolt-on acquisitions.
There is no rush. It has to be right.
With a solid foundation and a clear strategy focused on efficiency, financial discipline, and growth through organic means and acquisitions, we are well-positioned to deliver sustainable value for our clients and shareholders.
Thank you for joining today.
We open up for questions.